Danaher Corporation (DHR)
| Market Cap | 141.13B |
| Revenue (ttm) | 24.01B |
| Net Income (ttm) | 3.41B |
| Shares Out | 716.05M |
| EPS (ttm) | 4.71 |
| PE Ratio | 41.82 |
| Forward PE | 24.28 |
| Dividend | $1.28 (0.65%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 5,735,776 |
| Open | 195.33 |
| Previous Close | 197.16 |
| Day's Range | 192.26 - 197.16 |
| 52-Week Range | 171.00 - 281.70 |
| Beta | 0.76 |
| Analysts | Strong Buy |
| Price Target | 260.29 (+32.07%) |
| Earnings Date | Jul 22, 2025 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manuf... [Read more]
Financial Performance
In 2024, Danaher's revenue was $23.88 billion, a decrease of -0.06% compared to the previous year's $23.89 billion. Earnings were $3.90 billion, a decrease of -17.79%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for DHR stock is "Strong Buy." The 12-month stock price target is $260.29, which is an increase of 32.07% from the latest price.
News
Danaher Appoints Jonathan Leiken as General Counsel
WASHINGTON , July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vic...
Investors decided the good outweighs the bad with Danaher, says Jim Cramer
'Mad Money' host Jim Cramer talks how to play Danaher after earnings.
Danaher Q2 2025 Update
While the worst seem to be behind them, the business isn't quite humming enough to get investors excited yet. Revenue growth guidance for 2025 remains unchanged at 3%. But they did raise full year adj...
Danaher Stock: Attractively Valued And Poised For Growth Acceleration
Danaher Corporation is returning to growth, led by strong bioprocessing demand and resilient diagnostics, with Life Sciences expected to recover in late 2025. Margins may face short-term pressure, but...
Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript
Danaher Corporation (NYSE:DHR) Q2 2025 Earnings Conference Call July 22, 2025 8:00 AM ET Company Participants John Bedford - Vice President of Investor Relations Matthew R. McGrew - CFO & Executive V...
Cramer's Stop Trading: Danaher
Jim Cramer breaks down why he's keeping an eye on shares of Danaher.
Danaher lifts annual profit view on strength in diagnostics, names new CFO
Life sciences firm Danaher raised its annual profit forecast on Tuesday, banking on resilient demand for its diagnostic testing tools and services.
Danaher Announces Transition Plan for Chief Financial Officer
WASHINGTON , July 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Matthew Gugino, currently Group Chief Financi...
Danaher Reports Second Quarter 2025 Results
WASHINGTON , July 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 27, 2025. Key Second Quarter 2025 Results Net earnings wer...
45 Barron's 2025 Mid-Year Pro-Picks: 3 Ideal July DiviDogs
I analyze Barron's Mid-Year 2025 Roundtable Pro Picks using the yield-based 'dogcatcher' method to identify high-yield, safer dividend stocks. AT&T, Tegna, and Pitney Bowes stand out as 'safer' divide...
Danaher: Biotech Momentum, Cost Cuts And Valuation Re-Rating Should Drive Upside
Danaher is positioned for a revenue rebound, led by strong bioprocessing demand and resilient recurring sales, despite short-term headwinds in Life Sciences and China. Margin outlook is stable, suppor...
Danaher Appoints Martin Stumpe as Chief Technology and AI Officer
WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technol...
Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences
WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Boa...
Danaher: High Capex And Low Debt Despite Trump Legislation
The company has achieved returns on equity above 7.8% since 2019. Additionally, it reduced its liabilities-to-assets ratio to 35.72% this quarter, indicating a low risk of bankruptcy. Danaher expects ...
Danaher Schedules Second Quarter 2025 Earnings Conference Call
WASHINGTON , June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 b...
Prosperity Partners Completes Acquisition of Danaher Attig & Plante
CHICAGO--(BUSINESS WIRE)--Prosperity Partners (“Prosperity”), a Chicago-headquartered tax and accounting business backed by Unity Partners LP (“Unity Partners”), today announced that it has completed ...
SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #ZenoTOF--At ASMS 2025, SCIEX launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation.
Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #AI--SCIEX announces three software ecosystem enhancements at ASMS, supporting the theme that “all science is data science now.”.
SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Evocep--SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement.
Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid...
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR) BofA Securities 2025 Healthcare Conference May 15, 2025 1:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Mike Ryskin - Bank of America Mi...
Danaher to Present at Bank of America Securities Healthcare Conference
WASHINGTON , May 7, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securit...
Danaher Announces Quarterly Dividend
WASHINGTON , May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common sto...
Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity
Danaher Corporation's intrinsic value is estimated at $213 per share, suggesting a 14% upside from the current price of $187, with a 12% margin of safety. Despite revenue growth driven by acquisitions...